BioRestorative Therapies, Inc. ("BioRestorative,” "BRTX” or the "Company”) (NASDAQ: BRTX), a clinical-stage regenerative me ...

Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of only 15 months despite ...

Bioprinted epiblast-like structures mimic early human embryonic development, offering a scalable, ethical platform to study ...

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield – targeting tumours in a way that finally ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...